Saxagliptin
- Generic Name
- Saxagliptin
- Brand Names
- Kombiglyze, Komboglyze, Onglyza, Qtern, Qternmet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25N3O2
- CAS Number
- 361442-04-8
- Unique Ingredient Identifier
- 8I7IO46IVQ
- Background
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
- Indication
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Nanjing Medical University
- Target Recruit Count
- 184
- Registration Number
- NCT02307695
- Locations
- 🇨🇳
First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Prof. Dr. Thomas Forst
- Target Recruit Count
- 64
- Registration Number
- NCT02304081
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Germany
Effects of Saxagliptin on Adipose Tissue Inflammation in Humans
- Conditions
- Interventions
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Phoenix VA Health Care System
- Target Recruit Count
- 103
- Registration Number
- NCT02285985
- Locations
- 🇺🇸
Carl T. Hayden VA Medical Hospital, Phoenix, Arizona, United States
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 461
- Registration Number
- NCT02284893
- Locations
- 🇿🇦
Research Site, Soweto, South Africa
Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2018-07-23
- Target Recruit Count
- 388
- Registration Number
- NCT02280486
- Locations
- 🇨🇳
at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 689
- Registration Number
- NCT02243176
- Locations
- 🇨🇳
Research Site, Shanghai, China
DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Ram Weiss
- Target Recruit Count
- 60
- Registration Number
- NCT02239458
- Locations
- 🇮🇱
Hadassah Ein Kerem/Har Hazofim, Jerusalem, Israel
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02223065
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT02182895
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Cystic Fibrosis Related Diabetes
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Ram Weiss
- Target Recruit Count
- 30
- Registration Number
- NCT02148978
- Locations
- 🇮🇱
Hadassah Har Hazofim, Jerusalem, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.